Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
Status:
Terminated
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease
will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then
surgical resection for those with resectable or borderline resectable disease. The primary
endpoint is disease-free survival at 1 yr from initiation of treatment.